Back to the Top 100
Lunit logo

Rank 17AI & Clinical Intelligence

Lunit

Develops AI-powered software for cancer diagnostics and therapeutics, analyzing mammography, chest X-rays, and tissue pathology slides.

Visit website
Signal Score
91.9
Total raised
$140M
Stage
Public
Founded
2013
Headquarters
Seoul, South Korea
Region
Asia-Pacific

Their signal

Lunit's global footprint and deep clinical validation make it a premier medical AI provider, expanding rapidly into global national screening programs.

Signal Score 91.9editorial estimate, see how it is built
Capital (25% weight)93

Total raised, quality of investors and recency of the last round.

Growth (25% weight)91

Revenue trajectory, customer count, hiring and market pull.

Clinical & regulatory (20% weight)96

Peer-reviewed evidence, FDA/CE clearances and live health-system deployments.

Team (15% weight)90

Founder track record, clinical depth on the bench and technical leadership.

Online visibility (15% weight)88

Search presence, press coverage, founder and brand reach, and how often the company shows up where buyers look.

Also in AI & Clinical Intelligence

Figures are subjective research desk estimates compiled from public sources and refreshed daily, published as editorial commentary. Company marks are shown for identification only and imply no endorsement or affiliation. Want a correction, an update or removal? and see our corrections and removals policy.